每日经济新闻消息，近日，英国首相斯塔默开启为期4天的访华行程，此次访问是英国首相时隔8年再次 访华。英国政府公布的代表团名单显示，随同斯塔默访问的有超50家企业高管和机构代表，涵盖金融、 医药、制造业、文化等领域。 其中，阿斯利康全球首席执行官苏博科、葛兰素史克董事会主席司明麒作为英国医药产业的代表随团访 华。 原标题：英国首相斯塔默访华引来重磅投资，阿斯利康宣布将于2030年前在中国投资超千亿元 在当前全球医药产业链加速重构、创新药研发成本持续攀升的背景下，中国凭借完善的产业配套、庞大 的临床资源和不断优化的审评审批环境，正成为跨国药企的研发热土。阿斯利康、葛兰素史克等跨国药 企近年来持续加码在华投入，在研发中心建设、创新药本土化开发等方面动作频频。 编辑：黄灵 责编：王光建 审核：张松涛 1月29日，阿斯利康宣布，计划于2030年前在中国投资逾1000亿元人民币（150亿美元），以扩大在药品 生产与研发领域的布局。 阿斯利康方面表示，该项投资将显著增强公司在细胞治疗和放射偶联药物方面的能力，推动公司广泛多 元化产品管线发展，惠及癌症、血液病和自身免疫性疾病等患者。这些投资将覆盖从药物发现、临床开 发到生产 ...

Core Insights - The attractiveness of the Chinese market is a primary driver for multinational pharmaceutical companies to increase investments in China [3] - The Chinese government's support for innovative drugs has bolstered the confidence of multinational companies in investing in the country [4] Group 1: Investment Trends - AstraZeneca reported a 5% year-on-year revenue growth in China for the first three quarters, reaching $5.279 billion, accounting for over 12% of its global revenue [3] - Novartis achieved $3.2 billion in sales in China, also reflecting a 5% year-on-year growth [3] - Novo Nordisk's revenue in China reached $2.234 billion, with an 8% year-on-year increase [3] - Eli Lilly's sales in China grew by 20% year-on-year, totaling $1.477 billion [3] - Sanofi's sales in China amounted to $1.3 billion [3] Group 2: Government Support and Policy Changes - The National Healthcare Security Administration (NHSA) showcased its role as a significant global pharmaceutical purchaser at the China International Import Expo [4] - The NHSA and the National Health Commission released measures to support the high-quality development of innovative drugs, including 16 specific initiatives [4] - Approximately 80% of innovative drugs can be included in the medical insurance directory within two years of market approval [4] Group 3: Company-Specific Investments - AstraZeneca announced an additional investment of approximately $136 million to expand its production capacity in Qingdao, bringing its total investment in the area to $886 million [5] - Roche plans to invest 2.04 billion yuan in a new biopharmaceutical production base in Shanghai to enhance its local supply chain [6] - Eli Lilly is establishing an innovation incubator in Shanghai and has invested over 20 billion yuan in China to create a full industry chain from R&D to commercialization [8] - Sanofi is investing 1 billion euros in a new insulin raw material project in Beijing, marking the largest investment in the pharmaceutical industry in the city since the 14th Five-Year Plan [12] Group 4: Market Dynamics - The insulin market in China is projected to reach 32 billion yuan by 2024, with foreign companies holding a combined market share of 75% in third-generation insulin products [13]